Drug
Melphalan clinical trials
Also written Alkeran, L-PAM and CB-3025.
Includes 12 studies of Melphalan hydrochloride.
How each study uses Melphalan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Melphalan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Jan 1964 · ALKERAN · NDA 014691 (FDA, Drugs@FDA)
- European Union
- 16 Nov 2020 · Phelinun · EMEA/H/C/005173 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
398 studies that test it; most in 2009 (21); 4 more planned to start later
| Year | Studies |
|---|---|
| 1992 | 2 |
| 1993 | 1 |
| 1994 | 2 |
| 1995 | 3 |
| 1996 | 3 |
| 1997 | 6 |
| 1998 | 13 |
| 1999 | 16 |
| 2000 | 12 |
| 2001 | 16 |
| 2002 | 16 |
| 2003 | 7 |
| 2004 | 16 |
| 2005 | 17 |
| 2006 | 16 |
| 2007 | 19 |
| 2008 | 19 |
| 2009 | 21 |
| 2010 | 15 |
| 2011 | 17 |
| 2012 | 16 |
| 2013 | 20 |
| 2014 | 20 |
| 2015 | 10 |
| 2016 | 10 |
| 2017 | 11 |
| 2018 | 13 |
| 2019 | 8 |
| 2020 | 9 |
| 2021 | 12 |
| 2022 | 7 |
| 2023 | 11 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 383
M.D. Anderson Cancer Center (41) · Memorial Sloan Kettering Cancer Center (22) · City of Hope Medical Center (21) · Fred Hutchinson Cancer Center (20) · Masonic Cancer Center, University of Minnesota (14) · Children's Oncology Group (10) · National Cancer Institute (NCI) (10) · Delcath Systems Inc. (7)
Often tested with
Tested in the same studies.
Fludarabine (109) · Busulfan (88) · Cyclophosphamide (87) · Etoposide (62) · Thiotepa (47) · Fludarabine phosphate (37) · Cytarabine (32) · Dexamethasone (32)
Related medicines
As reviewed, each with the page that says it.
- One of Alkylating agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 6 phase 3 studies under way
Melphalan is the comparator. A study of two new drugs counts under both.
- 1Bortezomib · University of Arkansas · next primary completion Sep 2027
- 1Carfilzomib · PETHEMA Foundation
- 1Daratumumab · PETHEMA Foundation
- 1Anitocabtagene autoleucel · Kite, A Gilead Company · next primary completion Mar 2039
- 1Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F · AstraZeneca · next primary completion Nov 2028
- 1Isatuximab · Dana-Farber Cancer Institute · next primary completion Oct 2033
- 1Tucidinostat · Sichuan University
Reaching primary completion within a year · 22, 2 in phase 3
Studies that test Melphalan, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Sep 2027Twice-per-weekSelinexor, 2 Days MelphalanPhase 3 · Institute of Hematology & Blood Diseases Hospital, China
- Nov 2026Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell TransplantationPhase 2 · Emory University
- Nov 2026A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly PatientsPhase 1 · Memorial Sloan Kettering Cancer Center
- Nov 2026Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTPhase 2 · Paul Szabolcs
- Dec 2026Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseasePhase 2 · Delcath Systems Inc.
- Dec 2026HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisPhase 2 · Center for International Blood and Marrow Transplant Research
- Jan 2027Reduced Intensity Haploidentical BMT for High Risk Solid TumorsPhase 2 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Jan 2027Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersPhase 2 · Masonic Cancer Center, University of Minnesota
- Jan 2027STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAPhase 4 · University of Turin, Italy
Studies
Open first, then newest update. How each study uses Melphalan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 404
- Auto Stem Cell Transplant for Lymphoma PatientsRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03125642Written as Melphalan
- Personalized NK Cell Therapy in CBTRecruitingPhase 2M.D. Anderson Cancer CenterNCT02727803Written as Melphalan
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Melphalan
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingPhase 1City of Hope Medical CenterNCT06287944Written as Melphalan
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as Melphalan
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT06954987Written as Melphalan
- Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseaseRecruitingPhase 2Delcath Systems Inc.NCT06607458Written as Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab
- CD34+ Enriched Transplants to Treat Myelodysplastic SyndromeNot yet recruitingNot applicableGuenther KoehneNCT05617625Written as Melphalan
- CD34+ Transplants for Myeloid MalignanciesNot yet recruitingPhase 2Guenther KoehneNCT05565105Written as Melphalan
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeRecruitingPhase 2City of Hope Medical CenterNCT07582172Written as Melphalan
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingPhase 1Vastra Gotaland RegionNCT05903937Written as Melphalan
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaRecruitingPhase 1St. Jude Children's Research HospitalNCT07257419Written as Melphalan
- A Study to Give Treatment Inside the Eye to Treat RetinoblastomaRecruitingPhase 2Children's Oncology GroupNCT05504291Written as Melphalan
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as Melphalan Hydrochloride
- Personalized Autologous Transplant for Multiple MyelomaRecruitingPhase 1Emory UniversityNCT04483206Written as Melphalan
- Haplo-Cord HSCT for AML/MDSRecruitingNot applicableFujian Medical University Union HospitalNCT07588360Written as Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingPhase 3SWOG Cancer Research NetworkNCT06022939Written as Melphalan
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT05735717Written as Melphalan
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 TrialRecruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT07396480Written as Venetoclax in combination with fludarabine and melphalan
- Reduced Intensity Haploidentical BMT for High Risk Solid TumorsRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01804634Written as Melphalan
See all 404 studies that test Melphalan →
Given beside what is tested · 162 — Melphalan is usual care or a partner of the new treatment
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingPhase 1/2National Cancer Institute (NCI)NCT05436418Written as Melphalan
- Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06996119Written as Melphalan
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingPhase 3National Cancer Institute (NCI)NCT06172296Written as Melphalan
- Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk NeuroblastomaRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT02605421Written as Melphalan
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as Melphalan
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07228624Written as Melphalan
- A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06679829Written as Melphalan
- MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06377540Written as Melphalan
- Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic MelanomaNot yet recruitingPhase 1Vastra Gotaland RegionNCT07183852Written as Melphalan
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06207799Written as Melphalan
- Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary MyelofibrosisRecruitingPhase 2Fred Hutchinson Cancer CenterNCT04370301Written as Melphalan
- Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell TransplantRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04022239Written as Melphalan
- Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningRecruitingPhase 2City of Hope Medical CenterNCT06815003Written as Melphalan
- TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic MalignanciesRecruitingPhase 1St. Jude Children's Research HospitalNCT07052370Written as Melphalan
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsRecruitingPhase 1General Oncology, Inc.NCT04150042Written as Melphalan
- Autologous Stem Cell Transplantation for Crohn's DiseaseRecruitingPhase 1/2Paul SzabolcsNCT00692939Written as Melphalan
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingPhase 2Wuhan Union Hospital, ChinaNCT06140966Written as Melphalan
- Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma PatientsRecruitingPhase 2Insel Gruppe AG, University Hospital BernNCT05636787Written as Melphalan
- Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNot applicableRuijin HospitalNCT05863845Written as Melphalan
- Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingPhase 2University of LiegeNCT03852407Written as Melphalan
Showing 20 of 162.
As the comparator · 16 — what is tested is compared with Melphalan
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07903506Written as Melphalan
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).RecruitingPhase 3AstraZenecaNCT07735637Written as Melphalan (part of ASCT)
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMRecruitingPhase 3Dana-Farber Cancer InstituteNCT07624513Written as Melphalan
- Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic TransplantationRecruitingPhase 2Technische Universität DresdenNCT07025824Written as Melphalan (Mel)
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingPhase 3Sichuan UniversityNCT05466318Written as Melphalan
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk MyelomaActive, not recruitingPhase 3University of ArkansasNCT00734877Written as M-VTD-PACE
- A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Active, not recruitingPhase 2University of BirminghamNCT03821610Written as Melphalan
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or OlderTerminatedPhase 2Hackensack Meridian HealthNCT01453088Written as Melphalan
- Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisTerminatedPhase 3Millennium Pharmaceuticals, Inc.NCT01659658Written as Melphalan
- Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsActive, not recruitingPhase 3PETHEMA FoundationNCT03742297Written as Melphalan
- A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell ReinfusionStatus unknownPhase 2Swedish Medical CenterNCT03570983Written as Melphalan
- Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple MyelomaCompletedPhase 3University Hospital, ToulouseNCT02197221Written as Melphalan
- Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCTStatus unknownPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT03385096Written as Melphalan
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedPhase 3CelgeneNCT00689936Written as Melphalan, Prednisone and Thalidomide
- BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's LymphomaCompletedPhase 2Soonchunhyang University HospitalNCT03794167Written as Melphalan
- Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose DexamethasoneCompletedPhase 2PETHEMA FoundationNCT01237249Written as Melphalan
What changed recently
From the registry's own updates since Oct 15, 2026.
Newly registered1
Codes
What other systems call Melphalan · ClinicalTrials.gg INT007784
- MeSH (NLM) D008558MelphalanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Q41OR9510PMELPHALANConfirmed FDA, NLM, Wikidata
- RxNorm 6718Confirmed FDA, Wikidata
- Wikidata Q2298283melphalanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C633MelphalanOne source FDA
- DrugBank DB01042One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D008558 | Melphalan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Q41OR9510P | MELPHALAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 6718 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2298283 | melphalan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C633 | Melphalan | One source FDA |
| DrugBank | DB01042 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.